The company is now commencing a trial of the test platform in 250 patients to generate more data while it considers how to best commercialize it.
The firms are collaborating to develop a solution that includes Nightingale's nuclear magnetic resonance assay and PerkinElmer's sequencing services.
Numares will use its technology to advance work by Oxford researchers to create a noninvasive test to better diagnose MS.
The firm has settled on a set of metabolite biomarkers, along with an algorithm, for its first version of a test for arterial plaque buildup.
Researchers from the US and UK used a combination of genetic and metabolomics analyses to home in on methylthioadenosine as sepsis biomarker.
The non-exclusive licensing and distribution deal with Evolution Labs makes PolypDx available in five states.